EcoDrugPlus

Interleukin-6-Like

Ensembl ID : ENSMAMG00000010281
Gene Symbol: LOC113126494
2 Cross references
162 Possible Orthologues:

Inward Rectifier Potassium Channel 2-Like

Ensembl ID : ENSMAMG00000021399
Gene Symbol: LOC113141377
2 Cross references
202 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSMAMG00000012331
Gene Symbol: IDH1
3 Cross references
234 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSMAMG00000008807
Gene Symbol: IDH2
4 Cross references
207 Possible Orthologues:

Isotocin Receptor-Like

Ensembl ID : ENSMAMG00000027583
Gene Symbol: LOC113130965
2 Cross references
183 Possible Orthologues:

Kappa-Type Opioid Receptor-Like

Ensembl ID : ENSMAMG00000005750
Gene Symbol: LOC113121614
2 Cross references
197 Possible Orthologues:

Kelch-Like Ech-Associated Protein 1b

Ensembl ID : ENSMAMG00000002679
Gene Symbol: KEAP1B
3 Cross references
189 Possible Orthologues:

Kinase Insert Domain Receptor (A Type Iii Receptor Tyrosine Kinase)

Ensembl ID : ENSMAMG00000014979
Gene Symbol: KDR
3 Cross references
197 Possible Orthologues:

Kinesin Family Member 5b

Ensembl ID : ENSMAMG00000013863
Gene Symbol: KIF5B
3 Cross references
234 Possible Orthologues:

Kinesin-1 Heavy Chain

Ensembl ID : ENSMAMG00000011033
Gene Symbol: LOC113134020
2 Cross references
236 Possible Orthologues:

Lectin, Galactoside Binding Soluble 3a

Ensembl ID : ENSMAMG00000000195
Gene Symbol: LGALS3A
3 Cross references
220 Possible Orthologues:

Leukotriene A4 Hydrolase

Ensembl ID : ENSMAMG00000021165
Gene Symbol: LTA4H
2 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).